
ASHPOfficial is the premier podcast of ASHP and the collective voice of our 50,000 members in health-system pharmacy. Through interviews and discussions with pharmacy thought leaders, ASHPOfficial will explore issues related to public health, medication use, and supporting the professional practice of pharmacists in hospitals, health systems, ambulatory clinics, and other settings. To learn more about ASHP, please visit ashp.org.
Episodes

Tuesday Mar 02, 2021
2021 ASHP/ASHP Foundation Pharmacy Forecast
Tuesday Mar 02, 2021
Tuesday Mar 02, 2021
In this podcast, Janet Carmichael, Joseph DiPiro, and Rita Shane will discuss the 2021 ASHP/ASHP Foundation Pharmacy Forecast Report with host and AJHP Editor in Chief Daniel Cobaugh. They will focus on the Report’s findings and recommendations related to big data, patient safety, and health disparities as well as its relationship to the Vizient High Value Pharmacy Enterprise Framework and its role in strategic planning for pharmacy departments.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Monday Mar 01, 2021
Pharmacy Leadership: Going knocking for opportunity
Monday Mar 01, 2021
Monday Mar 01, 2021
This podcast will describe how you can evaluate which activities to pursue and thoughtfully determine which ones will help you achieve sustainable success. It also explores how to approach systematically evaluating an opportunity to optimize efficiency.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Friday Feb 26, 2021
Friday Feb 26, 2021
This podcast episode traces the unique professional journey of Jasper (Jay) Watkins, III. A retired Lieutenant Colonel in the U.S. Army, Watkins recently took office as a member of the Gwinnett County, Georgia Commission. Listeners will hear highlights from Watkins’ more than two decades in pharmacy practice, his motivation for transitioning to a different aspect of public service, and the ways he thinks pharmacy will influence his time in office.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Thursday Feb 25, 2021
Therapeutic Thursdays: Atrial Fibrillation Rate vs Rhythm Debate
Thursday Feb 25, 2021
Thursday Feb 25, 2021
This podcast explores the nuances of rate and rhythm control in atrial fibrillation. The Early Rhythm Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4) Trial that was published in October 2020 will also be discussed. For today’s debate, Danielle will promote rhythm control while Riley argues that rate control remains the strategy of choice.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Thursday Feb 25, 2021
Therapeutic Thursdays: ASHP Guidelines on Emergency Medicine Pharmacist Services
Thursday Feb 25, 2021
Thursday Feb 25, 2021
This podcast reviews the newly revised ASHP Guidelines on Emergency Medicine Pharmacist Services. Originally released in 2011, a group of emergency medicine clinical pharmacy specialist content experts conducted a literature search for updated supporting evidence and updated the recommendations to establish reasonable goals on attainable best practices.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Wednesday Feb 24, 2021
Wednesday Feb 24, 2021
In this presentation from the 2020 Midyear Clinical Meeting, content matter experts describe clinical trial designs for COVID-19 vaccine candidates, identify important documentation requirements and safety surveillance measures and actions, outline opportunities to address vaccine hesitancy, calculate the number needed to vaccinate to stop widespread community transmission of SARS CoV-2 and discuss clinical implications related to COVID-19 vaccine(s) made available through Emergency Use Authorization.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Tuesday Feb 23, 2021
Tuesday Feb 23, 2021
MCM COVID-19 Presentation: Roadmap to a COVID-19 Vaccine: Clinical Considerations for Ensuring Safety and Efficacy Part 1Vaccine Clinical Trial Design and Vaccine Development During a Pandemic
In this presentation from the 2020 Midyear Clinical Meeting, content matter experts describe clinical trial designs for COVID-19 vaccine candidates, identify important documentation requirements and safety surveillance measures and actions, outline opportunities to address vaccine hesitancy, calculate the number needed to vaccinate to stop widespread community transmission of SARS CoV-2 and discuss clinical implications related to COVID-19 vaccine(s) made available through Emergency Use Authorization.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Monday Feb 22, 2021
Emerging Sciences: Emergency Use Authorization
Monday Feb 22, 2021
Monday Feb 22, 2021
In today's episode, we take listeners on a deeper dive of specific details of FDA Emergency Use Authorizations: what they are, what they are not, how they are determined, specific nuances that they may subsequently enact, and how they are determined for approval. The topic is intended to be general around EUA’s, but COVID-19 specific examples are highlighted as well as those that have brought public attention to the EUA process.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Thursday Feb 18, 2021
Thursday Feb 18, 2021
This two-part podcast series provides listeners with a review of updates to the diabetes treatment guidelines. Speakers share an overview of guideline updates, evaluate treatment options, and discuss methods of addressing issues related to affordability and access to medications.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Tuesday Feb 16, 2021
Tuesday Feb 16, 2021
In this interprofessional conversation, expert faculty discuss the clinical effects of neuromuscular blocking and reversal agents, including key components of NMB and reversal strategies during the intraoperative phase of care and neuromuscular monitoring. Patient risk factors and mitigation of post-operative complications will also be discussed.
To learn more about neuromuscular blockade and reversal visit www.ashpadvantage.com/nmbreversal/
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
